Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Natera is a global leader in cell-free DNA (cfDNA) testing and genetic diagnostics. The company is dedicated to transforming disease management worldwide by harnessing the power of cfDNA to provide early and accurate insights. Natera's portfolio spans women's health (including non-invasive prenatal testing with Panorama®), oncology (with products like Signatera™ for molecular residual disease monitoring and personalized cancer treatment guidance), and organ health (assessing organ transplant rejection risk with Prospera™). They emphasize rigorous scientific validation, technological innovation, and a commitment to improving patient outcomes through accessible and actionable genetic information.
The Austin headquarters serves as the central command for Natera's global operations, housing executive leadership, research and development, corporate strategy, and administrative functions.
The facility is a state-of-the-art building featuring advanced laboratory spaces, collaborative workspaces, and infrastructure designed to support cutting-edge genetic research and development.
Natera fosters a mission-driven work culture focused on scientific excellence, innovation, and patient impact. The environment is typically fast-paced, collaborative, and encourages employees to contribute to advancements in genetic healthcare.
Relocating its headquarters to Austin allows Natera to tap into a rich talent pool, benefit from a favorable business environment, and expand its R&D and operational capabilities to support its global growth.
Natera has a significant global presence, offering its genetic testing services in numerous countries worldwide. This is achieved through a combination of direct sales forces, partnerships with distributors, and collaborations with international laboratories and healthcare institutions. Their tests are utilized by clinicians globally to support decision-making in women's health, oncology, and organ transplantation, making advanced genetic insights accessible to a broad patient population.
13011 McCallen Pass
Austin
Texas
USA
Address: 201 Industrial Rd, Suite 410, San Carlos, CA 94070
Serves as a major West Coast operational and R&D center, leveraging proximity to Silicon Valley's talent and biotech ecosystem for collaborations and technological advancements.
Address: Zernikedreef 8, 2333 CL Leiden, Netherlands
Manages Natera's expansion and presence in Europe, Middle East, and Africa (EMEA), ensuring compliance with regional standards and catering to local market needs in genetic testing.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Natera' leadership includes:
Natera has been backed by several prominent investors over the years, including:
Natera has maintained relative stability in its core executive team while making strategic additions to strengthen key areas. In the past year, notable appointments have focused on enhancing medical leadership in oncology and bolstering legal and business operations. No high-profile departures from the C-suite have been publicly announced, indicating continuity in strategic direction.
Discover the tools Natera uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Natera commonly uses the [first_initial][last_name]@natera.com email format for its employees. While other formats might exist in isolated cases, this is the predominant structure observed for professional communications.
flastname@natera.com (e.g., jdoe@natera.com)
Format
schhapman@natera.com
Example
90%
Success rate
GlobeNewswire • May 16, 2024
Natera, Inc. and Personalis, Inc. announced a collaboration to develop personalized, tumor-informed molecular residual disease (MRD) assays for pharmaceutical partners. The collaboration aims to combine Natera's Signatera technology with Personalis' NeXT Personal liquid biopsy assay to offer enhanced MRD testing solutions for cancer therapy development....more
Natera Investor Relations • May 7, 2024
Natera announced its financial results for the first quarter ended March 31, 2024. The company reported total revenues of $301.8 million, a 29% increase compared to the first quarter of 2023. They also highlighted strong test volume growth, particularly in oncology and women's health....more
GlobeNewswire • April 8, 2024
Natera presented 18 abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2024. The data highlighted the clinical utility of its Signatera MRD test in various cancers, including its ability to predict treatment response, monitor for recurrence, and inform adjuvant therapy decisions....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Natera, are just a search away.